86 related articles for article (PubMed ID: 28586242)
1. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Veltmaat L; Cortes J
Blood; 2024 Mar; 143(10):858-865. PubMed ID: 38194683
[TBL] [Abstract][Full Text] [Related]
2. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Žáčková D; Semerád L; Faber E; Klamová H; Stejskal L; Bělohlávková P; Karas M; Cmunt E; Černá O; Procházková J; Čičátková P; Kvetková A; Horňák T; Skoumalová I; Srbová D; Šálek C; Buffa D; Voglová J; Jurček T; Folta A; Ježíšková I; Žižková H; Machová Poláková K; Papajík T; Žák P; Jindra P; Svobodník A; Štěpánová R; Mayer J
Leukemia; 2024 Apr; 38(4):893-897. PubMed ID: 38472478
[No Abstract] [Full Text] [Related]
3. Chronic myeloid leukemia: room for improvement?
Baccarani M; Pane F; Rosti G; Russo D; Saglio G
Haematologica; 2017 Jul; 102(7):1131-1133. PubMed ID: 28655808
[No Abstract] [Full Text] [Related]
4. Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
Chen J; Gale RP
Leukemia; 2024 Feb; 38(2):463-464. PubMed ID: 38151660
[No Abstract] [Full Text] [Related]
5. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective.
Eckstein N; Röper L; Haas B; Potthast H; Hermes U; Unkrig C; Naumann-Winter F; Enzmann H
J Exp Clin Cancer Res; 2014 Feb; 33(1):15. PubMed ID: 24502453
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.
Hus I; Szymczyk A; Mańko J; Drozd-Sokołowska J
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106746
[TBL] [Abstract][Full Text] [Related]
7. Alterations in cellular metabolisms after Imatinib therapy: a review.
Kumar V; Singh P; Gupta SK; Ali V; Jyotirmayee ; Verma M
Med Oncol; 2022 May; 39(5):95. PubMed ID: 35570245
[TBL] [Abstract][Full Text] [Related]
8. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.
Iwasaki H; Toda S; Murayama D; Kato S; Matsui A
Mol Clin Oncol; 2021 Feb; 14(2):28. PubMed ID: 33414909
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.
Tiribelli M; Eskazan AE
Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
Eşkazan AE
Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?
Eşkazan AE
Br J Clin Pharmacol; 2019 Oct; 85(10):2241-2243. PubMed ID: 31393022
[No Abstract] [Full Text] [Related]
12. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
Eşkazan AE
Br J Clin Pharmacol; 2018 Aug; 84(8):1635-1638. PubMed ID: 29862545
[No Abstract] [Full Text] [Related]
13. Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.
Eskazan AE
Int J Clin Oncol; 2018 Apr; 23(2):400-401. PubMed ID: 29134363
[No Abstract] [Full Text] [Related]
14. [Effect of bortezomib in inducing apoptosis of imatinib-resistant K562 cells and the mechanism].
Hua JY; Zhou XH; Ouyang ST; Wu YB
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Aug; 37(8):1136-1139. PubMed ID: 28801299
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
Eskazan AE; Ozmen D
Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
[No Abstract] [Full Text] [Related]
16. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
18. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
